Please check your internet connection and try again.
## Mylotarg (gemtuzumab ozogamicin)
### Overview
Mylotarg is an antibody-drug conjugate targeting CD33, an antigen expressed on myeloid leukemia cells.
### Primary Indications
* Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) in remission after induction and consolidation chemotherapy.
* Treatment of adult patients with relapsed or refractory AML.
### Adult Dosing
**Newly Diagnosed AML (in combination with chemotherapy):**
* Administer 6 mg/m² intravenously on days 4, 7, and 10 of the first cycle of chemotherapy, and on day 4 of subsequent consolidation cycles as tolerated.
* Administer 3 mg/m² intravenously on days 4, 7, and 10 of the first cycle of chemotherapy, and on day 4 of subsequent consolidation cycles as tolerated (alternative recommended by some guidelines).
**Relapsed or Refractory AML:**
* Induction: 3 mg/m² intravenously once. If a partial or complete remission is achieved, administer a second dose of 3 mg/m² intravenously 2 to 4 weeks after the first dose.
* Consolidation: If remission is achieved after induction therapy, administer 3 mg/m² intravenously every 4 weeks for up to 6 cycles.
### Pediatric Dosing
Dosing in pediatric patients is not established.
### Dose Adjustments
* **Hepatic Impairment:** No specific dose adjustment recommended. Monitor liver function closely.
* **Renal Impairment:** No specific dose adjustment recommended. Monitor renal function closely.
### Contraindications
* None.
### Adverse Effects
* **Hepatotoxicity:** Including veno-occlusive liver disease (VOD)/sinusoidal obstruction syndrome (SOS), hyperbilirubinemia, and elevated transaminases. This is a serious and potentially fatal adverse event.
* **Myelosuppression:** Including neutropenia, thrombocytopenia, anemia, and febrile neutropenia.
* **Infusion-related reactions:** Including fever, chills, rash, and dyspnea.
* **Hemorrhagic events:** Including gastrointestinal and intracranial hemorrhage.
* **Nausea, vomiting, diarrhea.**
* **Fatigue.**
### Key Drug Interactions
* No significant drug interactions identified.
### Monitoring
* **Liver Function Tests (LFTs):** Monitor bilirubin and transaminases before and regularly during treatment. Discontinue or delay treatment for signs of severe hepatotoxicity.
* **Complete Blood Counts (CBCs):** Monitor hematologic parameters regularly.
* **Signs and Symptoms of Infusion Reactions:** Monitor during and after infusion.
* **Signs and Symptoms of Bleeding:** Monitor for any signs of hemorrhage.
### Clinical Pearls
* **Hepatotoxicity (VOD/SOS):** This is a critical toxicity. Patients with a history of VOD/SOS, elevated bilirubin, or elevated AST may be at increased risk. Close monitoring and prompt management are essential.
* **Infusion Reactions:** Premedication with an antihistamine and/or corticosteroid may be considered. Slowing the infusion rate may help manage mild reactions.
* **Hemorrhagic Events:** Patients with bleeding disorders or on anticoagulation therapy should be monitored closely.
***
*This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider to determine the best course of treatment for your specific condition. Verify current prescribing information before making any treatment decisions.*
